Fulcrum Therapeutics Inc (NAS:FULC)
$ 7.47 -0.03 (-0.4%) Market Cap: 464.29 Mil Enterprise Value: 238.89 Mil PE Ratio: 0 PB Ratio: 1.97 GF Score: 48/100

Fulcrum Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2022 / 05:00PM GMT
Release Date Price: $14.27 (-5.37%)
Aditya Jayanthi

Hi. Good afternoon, everyone. Thank you all for joining us today. My name is Adi Jayanthi from the health care investment banking team here at JPMorgan.

Just before we get started, you'll see a blue Ask A Question button on your screen. If you do have any questions for the presenters as they're going through, please feel free to submit them through that button and we will try to field those after the presentation. But it's my pleasure to introduce Bryan Stuart today, who's the CEO at Fulcrum Therapeutics. Bryan, over to you.

Bryan E. Stuart
Fulcrum Therapeutics, Inc. - President, CEO & Director

Thanks, Adi. We appreciate JPMorgan and the opportunity to present here today. So if you follow along with me on the slides today, we'll be making some forward-looking statements. And it really is a pleasure to be able to talk about Fulcrum and our approach and some of the meaningful progress that we've made over the course of the last year.

So our mission at Fulcrum is to treat the root cause of genetically defined rare diseases. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot